Prasugrel is effective and safe for neurointerventional procedures.

Area of Science:

• Neurology
• Cardiovascular Medicine
• Pharmacology

Background:

• Dual antiplatelet therapy with clopidogrel bisulfate and aspirin is standard for neurointerventional procedures.
• Patient non-responsiveness to clopidogrel is a significant clinical challenge.
• Prasugrel, effective in cardiovascular settings, lacks evaluation in neurointerventional procedures.

Purpose of the Study:

• To assess the safety and efficacy of prasugrel as an alternative to clopidogrel.
• To evaluate prasugrel in patients with clopidogrel non-responsiveness or allergies.

Main Methods:

• Retrospective review of 16 patients undergoing neurointerventional procedures who received prasugrel (January 2009 - July 2011).
• Systematic chart review including demographics, procedure details, and complications.
• Assessment of peri- and post-procedural complications, including hemorrhagic events.

Main Results:

• All patients demonstrated immediate therapeutic response to prasugrel, confirmed by P2Y12 inhibition studies.
• No ischemic complications were reported in the study cohort.
• No intracranial hemorrhage complications occurred in patients treated with prasugrel.

Conclusions:

• Prasugrel is a viable alternative antiplatelet agent for neurointerventional procedures.
• It is particularly suitable for patients who do not respond to clopidogrel.
• Further research is warranted to compare prasugrel's safety, efficacy, and cost-effectiveness against clopidogrel.